The collaboration seeks to evaluate the combination of VBI's cancer vaccine immunotherapeutic candidate, VBI-1901, and Agenus' monoclonal antibody, balstilimab, in patients who had tumor removal and radiotherapy, the companies said.
VBI-1901 is currently in a mid-stage study, where it showed "encouraging" tumor responses and improvement in overall survival compared with historical controls, the companies said.
Under the terms of the collaboration, VBI will sponsor the study and will be responsible for the execution of the trial, while Agenus will supply balstilimab.
Financial terms of the collaboration were not disclosed.
VBI Vaccines shares rose 3.8% in recent trading, while Agenus shares plummeted 9.2%.
Price: 0.67, Change: +0.02, Percent Change: +3.78
|Silo Pharma Board Authorizes $1 Million Share Buybac...|
|First Wave to Initiate Phase 2 Trial to Test Enhance...|
|Research Alert: CFRA Raises View On Shares Of The Ae...|
|European Equities Rebound in Tuesday Trading as Fran...|
|Sonoma Pharmaceuticals Signs Distribution Deal With ...|